- Home
- BRW vs AMRN Comparison
BRW vs AMRN Comparison
Compare BRW & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$15.54
Company Overview
Basic Information| Metric | BRW | AMRN |
|---|---|---|
| Founded | 1987 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.1M | 339.8M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | BRW | AMRN |
|---|---|---|
| Price | $6.88 | $15.54 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 222.1K | 105.1K |
| Earning Date | 01-01-0001 | 03-11-2026 |
| Dividend Yield | ★ 15.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.15 | $7.08 |
| 52 Week High | $8.30 | $20.90 |
Technical Indicators
Market Signals| Indicator | BRW | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 35.58 | 53.83 |
| Support Level | $6.83 | $14.50 |
| Resistance Level | $6.94 | $17.31 |
| Average True Range (ATR) | 0.07 | 0.92 |
| MACD | -0.00 | 0.17 |
| Stochastic Oscillator | 16.67 | 55.25 |
Price Performance
Historical Comparison BRW
AMRN
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.